To help meet the potentially complex needs of patients after prostate cancer treatment and offer the precision and care ...

Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have launched a clinical trial, called ANDROMEDA, to ...

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have opened a clinical trial that will look at whether ...

By Dr Wendy Winnall - PCFA Research Team It's unfortunate that prostate surgery does not always mean the end of prostate ...

While prostate cancer recurrence is a major cause of death in patients receiving localized treatment, there are other significant causes of mortality. While prostate cancer progression or recurrence ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Bi opsy of the P rostate A voidance S ...

XTANDI: the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical ...

Investigators designed and externally validated a prostate cancer death prediction model for risk stratification of men at the point of PSA screening.

Changes in benign tissues next to prostate tumors may provide an early warning for patients at higher risk for biochemical recurrence after a radical prostatectomy, a study by researchers at Case ...

June 22, 2011 — Patients who smoke at the time of their prostate cancer diagnosis are at higher risk for disease-specific mortality. In addition, smoking at the time of a prostate cancer diagnosis is ...